NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- Guangxi middle school student jumps from school building after stabbing classmate
- Village reaps benefits of millet harvest through collective effort
- Shanghai University leads global initiative
- NHSA releases new guidelines for long-term care insurance services
- Three trapped after coal mine accident in Northwest China
- 10th China Intl Copyright Expo set to open in Qingdao
